February 7, 2018 7:46am
Sector intelligence and perspective
Represents an awakening for investors and companies as to who owns their shares?
As algorithms and ETFs remind us of their leverage in pricing and exposure to volatility
These are just the beginnings of reverberations
As I stated, “The rapidity of the sell-off and the resulting buy-up is ALSO an indicator of DANGER – check your fundamentals!”
Pre-open indications: I am abstaining but have a predilection after the resulting downside and dramatic rebound
Out and about: Osiris (OSIR) another CEO is leaving as a new BOD member is also announced; Verastem (VSTM) has submitted a NDA to the FDA seeking full approval for its lead product candidate duvelisib, for the treatment of relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and accelerated approval for the treatment of relapsed or refractory follicular lymphoma (FL). Sangamo Therapeutics (SGMO) is presenting initial safety data from the CHAMPIONS Study, the P1/2 clinical trial evaluating SB-913 for the treatment of mucopolysaccharidosis (MPS) type II, a rare disease also known as Hunter syndrome.
Members only. Please login.